查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829860

2025年全球臨床腫瘤學下一代定序市場報告

Clinical Oncology Next Generation Sequencing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，臨床腫瘤學新一代定序市場快速擴張，市場規模從2024年的5.1億美元成長至2025年的5.8億美元，複合年成長率達13.9%。預測期內的成長得益於基因組學研究、癌症生物標記發現、技術進步以及監管核准的推進。

預計未來幾年，臨床腫瘤學新一代定序市場將快速成長，到2029年將達到9.4億美元，複合年成長率為12.7%。預測期內的成長歸因於癌症發生率的上升、精準醫療、免疫腫瘤學和液態切片。預測期內的主要趨勢包括綜合基因組分析 (CGP)、免疫腫瘤學、腫瘤進化和異質性、人工智慧和機器學習。

次世代定序(NGS) 是一種用於確定 DNA 片段內核苷酸序列的技術，常用於腫瘤學研究。 NGS 在識別罕見癌症突變、檢測遺傳性癌症突變攜帶者以及為標靶治療提供分子基礎方面發揮關鍵作用。

臨床腫瘤學NGS的主要技術包括離子半導體定序、焦磷酸測序、邊合成邊定序、即時定序、連接定序、可逆染料終止定序和奈米孔定序。離子半導體定序是一種基於檢測DNA聚合過程中釋放的氫離子的定序技術。臨床腫瘤學NGS可應用於篩檢、伴隨診斷和其他診斷用途等各個領域，並被各種終端用戶使用，包括醫院實驗室、臨床研究機構和診斷實驗室。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準產品的國內生產以及加快研發更具成本效益的材料來降低風險。

本研究報告是商業研究公司（The Business 次世代定序儀 Company）新研究報告系列的一部分，該系列提供臨床腫瘤學次世代定序儀市場統計數據，包括全球市場規模、各地區佔有率、臨床腫瘤學次世代定序儀次世代定序儀市場中的競爭對手、臨床腫瘤學下一代次世代定序儀。本臨床腫瘤學次世代定序市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的完整觀點。

未來五年12.7%的預測成長率比我們先前對該市場的預測略有下降0.2個百分點。下降的主要原因是美國與其他國家之間關稅的影響。美國可能會直接感受到這種影響，因為聚合酵素鏈鎖反應酶和半導體測序晶片的供應鏈中斷，這些晶片來自英國和英國等關鍵地區，這可能導致個性化癌症治療計劃的延遲和基因組檢測成本的增加。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，這種影響可能會更加廣泛。

全球癌症患者數量的不斷成長預計將在短期內成為臨床腫瘤學次世代定序儀市場的成長要素。根據美國癌症協會的數據，光是在美國，2021年就通報了190萬例新發癌症病例和60萬例癌症相關死亡病例。全球最常見的癌症類型是肺癌、攝護腺癌、大腸癌和乳癌，佔所有新發癌症病例的43%。因此，全球癌症發生率的上升預計將推動需求並促進臨床腫瘤學下一代定序市場的成長。

癌症發生率的上升預計將推動臨床腫瘤學次世代定序儀(NGS) 市場的成長。癌症是指一組以體內異常細胞不受控制地生長擴散為特徵的疾病。 NGS 在檢測癌症的新型和罕見突變方面發揮關鍵作用，有助於更好地了解個別腫瘤的分子基礎。例如，2024 年 5 月，美國政府機構國家癌症研究所報告稱，美國癌症倖存者人數約 1,810 萬人。預計到 2032 年這一數字將增加到 2,250 萬。到 2040 年，每年新增癌症病例數估計將達到 2,990 萬，癌症相關死亡人數估計為 1,530 萬人。因此，癌症發生率的上升是推動臨床腫瘤學下一代定序市場擴張的主要因素。

臨床腫瘤學新一代定序市場中的公司正加大對工作流程自動化的投資，以提高準確性並減少樣本間的差異。例如，安捷倫自動化解決方案公司開發了自動化系統，可實現更多並行反應，縮短樣本處理時間，提高樣本通量，並最大限度地降低樣本間的差異。此外，像Sophia Genetics這樣的公司正專注於數據驅動型醫療和DNA定序自動化，以增強診斷和治療能力。

臨床腫瘤學次世代定序儀市場的主要企業正在推出像 BenchMark ULTRA PLUS 系統這樣的創新產品，以增強其市場競爭力。 BenchMark ULTRA PLUS 系統對於臨床實驗室，尤其是從事癌症診斷和研究的實驗室來說是一個寶貴的工具，因為它確保了診斷測試的準確性和效率，並最終有助於改善患者照護。例如，2022 年 6 月，瑞士製藥公司羅氏宣布推出 BenchMark ULTRA PLUS 系統，這是一個用於組織染色的尖端平台。該系統可為臨床醫生提供快速且準確的檢測結果，幫助他們及時為患者做出治療決策。

2023年1月，美國科學儀器製造商安捷倫科技收購了Avida Biomed，收購金額未揭露。此次收購旨在增強安捷倫科技的次世代定序儀應用，尤其是其用於癌症研究的高性能標靶富集工作流程。透過整合Avida的創新技術，安捷倫旨在強化其精準醫療方法，並將其SureSelect產品組合拓展到臨床研究和診斷市場。 Avida Biomed是一家總部位於美國的生物技術公司，專注於臨床腫瘤學的次世代定序儀。

臨床腫瘤學次世代定序市場的主要企業包括賽默飛世爾科技、Oxford Nanopore Technologies、QIAGEN NV、Myriad Genetics、Illumina, Inc.、F. Hoffmann-La Roche、PerkinElmer、安捷倫科技、Pacific Biosciences of California、Caris Life Sciences、Paradi​​yia Diagnostics Inc、Biomatters Ltd、Partek Inc、Foundation Medicine Inc、Becton Dickinson and Company (BD)、Takara Bio Inc、Creative Biolabs、Mogene LC、Knome Inc、Genomaoma Software GmbH、CLC bio、GnuBIO Inc、Bio-Rad Laborator Inc、Genita、Genomics Inc. Laboratories Inc.、Sysmex Corporation、Veracyte Inc.、Zymo Research Corporation、ArcherDX Inc.、Cepheid、 Karius Inc.、OncoDNA SA、Personal Genome Diagnostics Inc.、PierianDx Inc.

2024年，臨床腫瘤學次世代定序儀市場最大的地區是北美。亞太地區是臨床腫瘤學次世代定序儀市場的第二大地區。臨床腫瘤學次世代定序市場報告涵蓋的地區包括亞太地區、西歐、東歐、北美、南美以及中東和非洲。

臨床腫瘤學下一代定序市場報告涵蓋的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、義大利、西班牙、加拿大

臨床腫瘤學新一代定序市場涵蓋具有先進功能和技術的基因定序設備的銷售，例如離子半導體定序、焦磷酸測序、邊合成邊定序 (SBS)、即時定序 (SMRT)、連接定序以及其他用於腫瘤學研究以確定臨床腫瘤學所需的鹼基序列的技術。市場價值包括服務提供者銷售或包含在服務產品中的相關商品的價值。僅包括營業單位之間交易或出售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球臨床腫瘤學次世代定序：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球臨床腫瘤學下一代定序市場：成長率分析
  • 全球臨床腫瘤學下一代定序市場表現：規模與成長，2019-2024
  • 全球臨床腫瘤學下一代定序市場預測：規模與成長，2024-2029，2034
  • 全球臨床腫瘤學次世代定序：總目標市場（TAM）

第6章 市場細分

  • 全球臨床腫瘤學下一代定序市場（按技術、性能和預測），2019-2024 年、2024-2029 年和 2034 年
  • 離子半導體序列
  • 焦磷酸測序
  • 合成序列
  • 即時序列
  • 連接定序
  • 可逆染料終止序列
  • 奈米孔定序
  • 全球臨床腫瘤學次世代定序市場的應用、效能與預測，2019-2024 年、2024-2029 年、2034 年
  • 篩檢
  • 伴隨診斷
  • 其他診斷
  • 全球臨床腫瘤學下一代定序市場（按最終用戶、性能和預測），2019-2024 年、2024-2029 年和 2034 年
  • 醫院檢查室
  • 臨床研究所
  • 診斷實驗室
  • 全球臨床腫瘤學次世代定序市場：依離子半導體定序細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 離子質子系統
  • AEON PGM系統
  • ION S5 系統
  • 其他離子半導體定序技術
  • 全球臨床腫瘤學次世代定序市場：焦焦磷酸測序定序細分（按類型）、績效與預測，2019-2024、2024-2029、2034
  • 454焦磷酸測序
  • 其他焦磷酸測序技術
  • 全球臨床腫瘤學次世代定序市場：依合成定序細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • Illumina定序技術
  • SOLiD定序技術
  • 其他合成定序技術
  • 全球臨床腫瘤學次世代定序市場：依即時定序類型、表現與預測細分，2019-2024 年、2024-2029 年、2034 年
  • PacBio RS II 系統
  • 續集系統
  • 其他即時定序技術
  • 全球臨床腫瘤學次世代定序市場：依連結定序類型細分、效能與預測，2019-2024 年、2024-2029 年、2034 年
  • 螺旋單分子定序
  • 其他連接定序技術
  • 全球臨床腫瘤學下一代定序市場：按可逆染料終止定序類型細分、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • Illumina HiSeq
  • Illumina NextSeek
  • 其他可逆染料終止定序技術
  • 全球臨床腫瘤學下一代定序市場：按奈米孔定序類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 牛津奈米孔技術（MinION、GridION、PromethION）
  • 其他奈米孔定序技術

第7章 區域和國家分析

  • 全球臨床腫瘤學下一代定序市場：2019-2024 年、2024-2029 年和 2034 年的區域表現和預測
  • 全球臨床腫瘤學次世代定序市場：國家、績效與預測（2019-2024、2024-2029、2034）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 臨床腫瘤學下一代定序市場：競爭格局
  • 臨床腫瘤學次世代定序市場：公司簡介
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
    • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer Inc.
  • Agilent Technologies Inc.
  • Pacific Biosciences of California Inc.
  • Caris Life Sciences
  • Paradigm Diagnostics
  • GATC Biotech AG
  • Macrogen Inc.
  • DNASTAR Inc.
  • Exosome Diagnostics Inc.
  • Biomatters Ltd.
  • Partek Inc.
  • Foundation Medicine Inc.
  • Becton Dickinson and Company（BD）
  • Takara Bio Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年臨床腫瘤學下一代定序市場：提供新機會的國家
  • 2029年臨床腫瘤學次世代定序市場：細分市場帶來新機會
  • 臨床腫瘤學下一代定序市場 2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r32453u

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

The forecast of 12.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for polymerase chain reaction enzymes and semiconductor-based sequencing chips, sourced from key regions such as Singapore and the UK, which could lead to delayed personalized cancer treatment plans and increased genomic testing costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
  • 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
  • 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
  • Subsegments:
  • 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
  • 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
  • 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
  • 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
  • 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
  • 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
  • 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
  • Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Agilent Technologies Inc.; Pacific Biosciences of California Inc.; Caris Life Sciences; Paradigm Diagnostics; GATC Biotech AG; Macrogen Inc.; DNASTAR Inc.; Exosome Diagnostics Inc.; Biomatters Ltd.; Partek Inc.; Foundation Medicine Inc.; Becton Dickinson and Company (BD); Takara Bio Inc.; Creative Biolabs; Mogene LC; Knome Inc.; Genomatix Software GmbH; CLC bio; GnuBIO Inc.; Bio-Rad Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation; ArcherDX Inc.; Cepheid; Karius Inc.; OncoDNA S.A.; Personal Genome Diagnostics Inc.; PierianDx Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Clinical Oncology Next Generation Sequencing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Clinical Oncology Next Generation Sequencing Market Growth Rate Analysis
  • 5.4. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

  • 6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing
  • Real Time Sequencing
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing
  • 6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Screening
  • Companion Diagnostics
  • Other Diagnostics
  • 6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • 6.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ion Proton System
  • Ion PGM System
  • Ion S5 System
  • Other Ion Semiconductor Sequencing Technologies
  • 6.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 454 Pyrosequencing
  • Other Pyro-Sequencing Technologies
  • 6.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Illumina Sequencing Technology
  • SOLiD Sequencing Technology
  • Other Synthesis Sequencing Technologies
  • 6.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real-Time Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PacBio RS II System
  • Sequel System
  • Other Real-Time Sequencing Technologies
  • 6.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Helicos Single Molecule Sequencing
  • Other Ligation Sequencing Technologies
  • 6.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Illumina HiSeq
  • Illumina NextSeq
  • Other Reversible Dye Termination Sequencing Technologies
  • 6.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oxford Nanopore Technologies (MinION, GridION, PromethION)
  • Other Nano-Pore Sequencing Technologies

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

  • 7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

  • 8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

  • 9.1. China Clinical Oncology Next Generation Sequencing Market Overview
  • 9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

  • 10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

  • 11.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
  • 11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

  • 12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

  • 13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

  • 14.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
  • 14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

  • 15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
  • 15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

  • 16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

  • 17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

  • 18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

  • 19.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

  • 20.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

  • 21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
  • 21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

  • 22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

  • 23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
  • 23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

  • 24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
  • 24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

  • 25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
  • 25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

  • 26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
  • 26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

  • 27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

  • 28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
  • 28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

  • 29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
  • 29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

  • 30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
  • 30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

  • 31.1. F. Hoffmann-La Roche Ltd.
  • 31.2. PerkinElmer Inc.
  • 31.3. Agilent Technologies Inc.
  • 31.4. Pacific Biosciences of California Inc.
  • 31.5. Caris Life Sciences
  • 31.6. Paradigm Diagnostics
  • 31.7. GATC Biotech AG
  • 31.8. Macrogen Inc.
  • 31.9. DNASTAR Inc.
  • 31.10. Exosome Diagnostics Inc.
  • 31.11. Biomatters Ltd.
  • 31.12. Partek Inc.
  • 31.13. Foundation Medicine Inc.
  • 31.14. Becton Dickinson and Company (BD)
  • 31.15. Takara Bio Inc.

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Recent Developments In The Clinical Oncology Next Generation Sequencing Market

35. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

  • 35.1 Clinical Oncology Next Generation Sequencing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Clinical Oncology Next Generation Sequencing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Clinical Oncology Next Generation Sequencing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer